Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration.

Yoichiro Yoshida,Daibo Kojima,Yasushi Takamatsu,Taisuke Matsuoka,Kazuo Tamura,Keita Noda,Tomoko Koganemaru,Fumiaki Kiyomi,Naoya Aisu,Toshiyuki Mera,Yuichi Yamashita,Suguru Hasegawa,Teppei Yamada,Ai Mogi

doi:10.1186/s40064-016-3579-1

Yoichiro Yoshida, Daibo Kojima + Show 12 more

Open Access

https://doi.org/10.1186/s40064-016-3579-1

Copy DOI

Journal: SpringerPlus	Publication Date: Oct 26, 2016
Citations: 6	License type: CC BY 4.0

Affiliation: Fukuoka University, Fukuoka University Hospital

Abstract

BackgroundDuring oxaliplatin chemotherapy administration via a peripheral vein, vascular pain requires changing of the intravenous infusion route on occasion. Vascular pain induced by anticancer drugs reduces the rate of patient continuation and completion of chemotherapy. Pain is presently appraised using subjective methods, such as the visual analog scale (VAS). However, because pain evaluation can vary depending on the physical state and mood of the patient at the time of assessment, it is desirable to evaluate pain objectively. PainVision PS-2100 (PV) is a medical device that was designed to objectively and quantitatively assess patient nociception and perception.MethodsThe present study examined the correlation of subjective and objective assessment of oxaliplatin-induced vascular pain using VAS and PV, respectively.ResultsVascular pain was assessed using both PV and VAS a total of 173 times for 58 colorectal cancer patients. Partial correlation analysis was performed to evaluate the relationship between PV and VAS. The mean PV and VAS scores were 44.5 (range: 0–596) and 24.8 (range: 0–100), respectively. The partial correlation coefficient was 0.408 (p < 0.0001).ConclusionsA strong correlation was not observed between the results, and a weak correlation was observed between VAS and PV scores. Objective evaluation of oxaliplatin-induced vascular pain will be required to help patients overcome vascular pain.

Highlights

During oxaliplatin chemotherapy administration via a peripheral vein, vascular pain requires changing of the intravenous infusion route on occasion
We reported that visual analog scale (VAS) and PV are useful to evaluate oxaliplatin-induced peripheral neuropathy with the aim of aiding treatment (Yoshida et al 2015c), there have been no reports concerning the use of these measures for the assessment of vascular pain (VP) due to oxaliplatin
We evaluated the effectiveness of DEX for controlling VP caused by oxaliplatin administration via a peripheral vein during XELOX therapy (Yoshida et al 2012)

Summary

Introduction

During oxaliplatin chemotherapy administration via a peripheral vein, vascular pain requires changing of the intravenous infusion route on occasion. Because pain evaluation can vary depending on the physical state and mood of the patient at the time of assessment, it is desirable to evaluate pain objectively. Pain is presently estimated using subjective methods, such as the visual analog scale (VAS) (McCormack et al 1988; DeLoach et al 1998; Fishbain et al 2016). VAS has become a common tool for the quantification of pain intensity and pain relief This method has proven to be a valid and reliable means to assess depression, pain, mood, and anxiety (McCormack et al 1988; Lener et al 2016). A method to objectively assess pain is required when evaluating drugs designed to improve VP

Objectives

Methods

Results

Discussion

Conclusion